Preşedintele Comitetului naţional de coordonare a activităţilor privind vaccinarea împotriva SARS-CoV-2, Valeriu Gheorghiţă, a declarat marţi că reacţiile adverse la serul AstraZeneca pot fi mai frecvente după prima doză, comparativ cu alte vaccinuri, dar scad la a doua administrare.
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2021/01/vaccin_astrazeneca_91461400-747x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/10/flu_shot_15712500-630x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/12/vaccin_52424500-747x420.png)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2021/01/vaccin_astrazeneca_91461400-747x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2017/02/istock_000011686797small_58501300-562x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2019/07/ursula_10556700-608x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/11/astra_02130500_37128400-747x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2021/01/vaccine_53622600-643x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2015/12/astrazeneca_87403700-754x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/11/screenshot_2020_09_16_at_09_43_56_79529400-752x420.png)
